Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 15, 2026

Sify reports Consolidated Financial Results for Q1 FY 2026-27

View original at globenewswire.com
Sify reports Consolidated Financial Results for Q1 FY 2026-27 Revenues of INR 12,352 Million. Adjusted EBITDA of INR 3,005 Million. Profit for the period INR 65 Million…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Adjusted EBITDA was INR 3,005 million, an increase of 42% over the same quarter last year.

    60% confidence

  • Revenue was INR 12,352 million, an increase of 15% over the same quarter last year.

    60% confidence

  • India's digital transformation is entering a phase of execution at scale, and Sify's integrated portfolio of Data Centers, Networks, and Digital Services positions it to support customers modernizing for an AI-enabled future.

    60% confidence

  • The cash balance at the end of the quarter was INR 4,597 million.

    60% confidence

  • During the quarter, Sify strengthened the operational foundations of its businesses through disciplined execution, improved resource utilization, and targeted investments, while continuing to invest in capacity expansion, network modernization, and technology platforms for AI, cloud, and data-intensive workloads.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com